P017 INFLIXIMAB REDUCES COLECTOMY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: COLECTOMY ANALYSIS FROM ACT1 AND ACT2
J F Colombel(European CanCer Organisation), W. Sandborn, Stephen B. Hanauer(Northwestern University), Gary R. Lichtenstein(University of Pennsylvania), Brian G. Feagan(Western University), Daniel Rachmilewitz(Hadassah Academic College), Adriana Segura Olson, P. Rutgeerts, Willem J.S. de Villiers(Stellenbosch University), B E Sands(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Jiadi Lu, Jewel Johanns(Johnson & Johnson (United States)), D. Present(Mount Sinai Medical Center)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k